Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

855 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan.
Hiramatsu N, Kasahara A, Nakanishi F, Toyama T, Tsujii M, Tsuji S, Kanto T, Takehara T, Kato M, Yoshihara H, Naito M, Katayama K, Hijioka T, Hagiwara H, Kubota S, Oshita M, Meren H, Masuzawa M, Haruna Y, Mita E, Suzuki K, Hayashi N. Hiramatsu N, et al. Among authors: takehara t. Hepatol Res. 2004 Jul;29(3):142-147. doi: 10.1016/j.hepres.2004.03.008. Hepatol Res. 2004. PMID: 15203077
Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?
Hiramatsu N, Oze T, Tsuda N, Kurashige N, Koga K, Toyama T, Yasumaru M, Kanto T, Takehara T, Kasahara A, Kato M, Yoshihara H, Katayama K, Hijioka T, Hagiwara H, Kubota S, Oshita M, Haruna Y, Mita E, Suzuki K, Ishibashi K, Hayashi N. Hiramatsu N, et al. Among authors: takehara t. Hepatol Res. 2006 Jul;35(3):185-9. doi: 10.1016/j.hepres.2006.03.008. Epub 2006 May 4. Hepatol Res. 2006. PMID: 16678478
Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C.
Hiramatsu N, Kurashige N, Oze T, Takehara T, Tamura S, Kasahara A, Oshita M, Katayama K, Yoshihara H, Imai Y, Kato M, Kawata S, Tsubouchi H, Kumada H, Okanoue T, Kakumu S, Hayashi N. Hiramatsu N, et al. Among authors: takehara t. Hepatol Res. 2008 Jan;38(1):52-9. doi: 10.1111/j.1872-034X.2007.00205.x. Epub 2007 Aug 20. Hepatol Res. 2008. PMID: 17714473
Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine.
Kurashige N, Hiramatsu N, Ohkawa K, Oze T, Inoue Y, Kurokawa M, Yakushijin T, Igura T, Kiso S, Kanto T, Takehara T, Tamura S, Kasahara A, Oshita M, Hijioka T, Katayama K, Yoshihara H, Hayashi E, Imai Y, Kato M, Hayashi N. Kurashige N, et al. Among authors: takehara t. Hepatol Res. 2008 May;38(5):450-6. doi: 10.1111/j.1872-034X.2007.00292.x. Epub 2007 Nov 21. Hepatol Res. 2008. PMID: 18034827
Early emergence of entecavir-resistant hepatitis B virus in a patient with hepatitis B virus/human immunodeficiency virus coinfection.
Kanada A, Takehara T, Ohkawa K, Kato M, Tatsumi T, Miyagi T, Sakamori R, Yamaguchi S, Uemura A, Kohga K, Sasakawa A, Hikita H, Kawamura K, Kanto T, Hiramatsu N, Hayashi N. Kanada A, et al. Among authors: takehara t. Hepatol Res. 2008 Jun;38(6):622-8. doi: 10.1111/j.1872-034X.2007.00307.x. Epub 2007 Dec 9. Hepatol Res. 2008. PMID: 18070052
Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis.
Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushijin T, Kurashige N, Inoue Y, Igura T, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Yoshihara H, Inoue A, Imai Y, Kato M, Kiso S, Kanto T, Takehara T, Kasahara A, Hayashi N. Kurokawa M, et al. Among authors: takehara t. Hepatol Res. 2009 May;39(5):432-8. doi: 10.1111/j.1872-034X.2008.00477.x. Epub 2009 Jan 16. Hepatol Res. 2009. PMID: 19207583
855 results